Neuropeptide

CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity

Retrieved on: 
Tuesday, March 26, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Human, PYY, Obesity, Neuropeptide, Appetite, Patient, Weight loss, Trial of the century, IND, Nausea, PYY3-36, Safety, Pharmacokinetics, Therapy, Vomiting, Y2R, Pharma, Food, DSM-IV codes, Pharmaceutical industry

With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.

Key Points: 
  • With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.
  • The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in a randomized, double-blind, placebo-controlled, single ascending dose study in otherwise healthy subjects with obesity.
  • PYY3-36 is an endogenous hormone secreted in the gut, which activates the neuropeptide Y2 receptor (Y2R) to reduce appetite and food intake.
  • “The preclinical program of CIN-110 underscores the potential for PYY to be a differentiated approach to treat obesity.

BeautyStat Unveils Breakthrough: Peptide Wrinkle Relaxing Moisturizer

Retrieved on: 
Monday, January 22, 2024
Wrinkle, Ulta Beauty, Beauty, Heart, Life, Perception, Merchandising, Generation X, Gen, PR, Vitamin C, Dicarboxylic acid, Skin, Pressure, Protein, ULTA, Neuropeptide, Ageing, Elasticity, Fine chemical

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- BeautyStat, a leading force in chemist-created skincare technology, is poised to redefine the beauty landscape once again with the introduction of Peptide Wrinkle Relaxing Moisturizer, launching on January 22nd, exclusively on ULTA.com and Beautystat.com, and rolling out to ULTA Beauty stores on February 4th.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- BeautyStat, a leading force in chemist-created skincare technology, is poised to redefine the beauty landscape once again with the introduction of Peptide Wrinkle Relaxing Moisturizer, launching on January 22nd, exclusively on ULTA.com and Beautystat.com, and rolling out to ULTA Beauty stores on February 4th.
  • "I believe in advancing gold standard ingredients to unlock their full potential for uncompromising benefits, said Ron Robinson, BeautyStat founder.
  • The new Peptide Wrinkle Relaxing Moisturizer is a product we know they will love, as it celebrates the beauty of aging, instead of masking it.
  • We're excited to be the exclusive partner to bring this product to our passionate beauty community and look forward to welcoming guests to experience the Wrinkle Relaxing Moisturizer in our stores and ulta.com ."

Global Wound Care: Tissue-Engineered Skin Replacements and Wound Modulators Market Report 2023: Featuring AbbVie, Integra LifeSciences, MiMedx, Organogenesis, Smith+Nephew & Wright Medical - ResearchAndMarkets.com 

Retrieved on: 
Wednesday, April 5, 2023
Health, Biotechnology, Obesity, Enzyme, Neuropeptide, Prevalence, Evidence-based medicine, Diabetes, COVID-19, Skin, Ageing, Science, Hormone, Incidence, Tissue engineering, Knowledge, B cell, Wound healing, Pharmaceutical industry

The "Global Wound Care: Tissue-Engineered Skin Replacements and Wound Modulators Market - 2023 Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wound Care: Tissue-Engineered Skin Replacements and Wound Modulators Market - 2023 Report" report has been added to ResearchAndMarkets.com's offering.
  • Over the past two decades, there has been an explosion of knowledge regarding the basic science of wound healing and a trend toward more evidence-based medicine.
  • In 2021, global sales of tissue-engineered skin replacements and wound modulators totaled more than $1.5bn, with skin replacements accounting for the vast majority of the market.
  • Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of the World.

The Worldwide Peptide Therapeutics Industry is Expected to Reach $58.4 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Health, Biotechnology, Population growth, Innovation, Lysine, Colon, Peptide, Administration, Liraglutide, CVD, Prevalence, Serum, Blood, Disorder, Hormone, Brain, Instability, Neuropeptide, Route of administration, Ageing, Protein, Pancreas, Inflammation, Medicine, Death, Disease, Half-life, Carbon, Hypercholesterolemia, DPP, Lung cancer, Growth hormone, Cardiovascular disease, Cancer, Absorption, Risk, Therapy, Lanreotide, Hyperglycemia, Water, Application, Organic acid, Breast cancer, Somatostatin, Plasma, Breast, Obesity, Fine chemical, Vaccine

The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.

Key Points: 
  • The Global Peptide Therapeutics Market size is expected to reach $58.4 billion by 2028, rising at a market growth of 6.3% CAGR during the forecast period.
  • Peptide therapeutics are polypeptides or peptides (oligomers or short polymers of amino acids) that are utilized to treat disorders.
  • Peptide treatments replicate natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands, and anti-infectives.
  • Liraglutide, the most popular diabetic medicine on the market, contains a lipid chain that increases plasma circulation and provides long-term absorption.

Kevin Guest Says Smile on World Smile Day, Increase Harmony, Relieve Stress, Boost Positive Feelings

Retrieved on: 
Thursday, October 6, 2022
Neuropeptide, Negativism, Life, Attention, Infection, NYSE, Meal, Blood pressure, Goal, Immune system, SALT, CEO, Smile, USNA, Dance, Hormone, USANA Health Sciences, Lifting, Name, Empathy, Human, Dentistry, Entertainment, Amazon

SALT LAKE CITY, Oct. 6, 2022 /PRNewswire/ -- For World Smile Day Oct. 7, bestselling author Kevin Guest is urging everyone to smile and reap health benefits.

Key Points: 
  • SALT LAKE CITY, Oct. 6, 2022 /PRNewswire/ -- For World Smile Day Oct. 7, bestselling author Kevin Guest is urging everyone to smile and reap health benefits.
  • "I make it my duty to find something to be cheerful about every day.
  • Instead of pushing people away with negativism, I work to draw them in with my smile."
  • Some people turn to a hobby to boost their mood and smile more.

Global Peptide Therapeutics Market & Clinical Trials Insight Report 2022: Market Set to Surpass US$ 75 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 6, 2022
Health, Pharmaceutical, Dermatology, Peptide therapeutics, US, Gastroenterology, Company, Bone, Peptide, Endocrinology, Contract, Prevalence, Indication, Insulin, Attention, Degenerative disease, Cancer, Diabetes, Therapy, Industry, Conditional sentence, Vaccine, Glucagon-like peptide-2, Genentech, Organic acid, Research, Lists of diseases, Growth, Sexual dysfunction, Fine chemical, Neuropeptide, Glycopeptide, Natriuresis, Dipeptide, Depsipeptide, Oligopeptide, Lipopeptide

The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests a promising future of peptide therapeutics in the forthcoming years.
  • Keeping the clinical pipeline into consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028.
  • Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report highlights:
    Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
    Peptide Therapeutics in Clinical trials: > 800 Drugs
    Peptide Therapeutics Commercially Available In Market: > 200 Drugs
    Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

Retrieved on: 
Wednesday, May 4, 2022
Sleep, Neuroscience, Jazz Pharmaceuticals, Narcolepsy, Psychiatry, Twitter, Health, EDS, Pharmacokinetics, Sleep paralysis, NASDAQ, Idiopathic hypersomnia, Excessive daytime sleepiness, Safety, Drug discovery, Patient, Commission, Risk, Orexin, Annual report, DNS, U.S. Securities and Exchange Commission, Sleep disorder, Neurology, Wakefulness, Cataplexy, Research, Head, Neuropeptide, Pharmaceutical industry, TSE, Jazz

DUBLIN and OSAKA, Japan, May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) today announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441.

Key Points: 
  • Sumitomo Pharma initiated a Phase 1 trial in Japan of DSP-0187 in November 2021 to evaluate safety, tolerability and pharmacokinetics in healthy volunteers.
  • "Orexin agonism is an exciting area of sleep disorder research and an approach that may be complementary to oxybate therapy.
  • "DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist, which is a novel small molecule compound originally created by Sumitomo Pharma by utilizing our advanced expertise in drug discovery for central nervous system disorders.
  • DSP-0187 is a potent, highly selective orexin-2 receptor agonist designed to activate orexin signaling.

Perricone MD Unveils New High Potency Hyaluronic Intensive Hydrating Serum

Retrieved on: 
Wednesday, April 27, 2022
Nicotinamide, Woman, Neiman Marcus, Organic acid, Macy's, Serum, Complex, SAN, QVC, DMAE, Hyaluronic acid, Trial of the century, Skin, Solution, Bloomingdale's, Ulta Beauty, Multimedia, The New York Times, Cosmetics, Dietary supplement, Neuropeptide, Nordstrom

SAN FRANCISCO, April 27, 2022 /PRNewswire/ -- Perricone MD, the brand that puts forth breakthrough, science-backed skincare solutions, announces its latest addition to the award-winning High Potency Collection with the launch of the High Potency Hyaluronic Intensive Hydrating Serum. This fast-absorbing, deeply nourishing serum instantly replenishes skin with essential moisture to promote visibly smoother, firmer and plumper skin.

Key Points: 
  • SAN FRANCISCO, April 27, 2022 /PRNewswire/ -- Perricone MD, the brand that puts forth breakthrough, science-backed skincare solutions, announces its latest addition to the award-winning High Potency Collection with the launch of the High Potency Hyaluronic Intensive Hydrating Serum.
  • "Since hyaluronic acid is a proven, go-to ingredient in skincare, we wanted to take a different approach when formulating our Hyaluronic Intensive Hydrating Serum," says Chief Marketing Officer, Robert Koerner.
  • The High Potency Hyaluronic Intensive Hydrating Serum (2 US fl.
  • Perricone MD was created by Dr. Nicholas Perricone, whose New York Times best-seller The Wrinkle Cure introduced the world to the benefits of an anti-inflammatory lifestyle.

Perricone MD Introduces the Cold Plasma Plus+ Concentrated Treatment Sheet Mask

Retrieved on: 
Tuesday, February 1, 2022
Iron metallic discoloration, SAN, The New York Times, Trial of the century, Face, Bloomingdale's, Neiman Marcus, Skin, Plasma, Woman, Phospholipid, Perricone, Ulta Beauty, Organic acid, John Foster Dulles, Six pack, Macy's, QVC, Multimedia, Solution, Cosmetics, Neuropeptide, Nordstrom

SAN FRANCISCO, Feb. 1, 2022 /PRNewswire/ -- Innovative and clinically-proven skincare brand Perricone MD, announces the launch of the Cold Plasma Plus+ Concentrated Treatment Sheet Mask.

Key Points: 
  • SAN FRANCISCO, Feb. 1, 2022 /PRNewswire/ -- Innovative and clinically-proven skincare brand Perricone MD, announces the launch of the Cold Plasma Plus+ Concentrated Treatment Sheet Mask.
  • The Cold Plasma Plus+ Concentrated Treatment Sheet Mask immediately leaves skin feeling renewed and rejuvenated.
  • The Cold Plasma Plus+ Concentrated Treatment Sheet Mask is not only potent and effective, but it also offers consumers the ultimate self-care experience," states Chief Marketing Officer, Robert Koerner.
  • The Cold Plasma Plus+ Concentrated Treatment Sheet Mask (single sheet, $19 and 6-pack, $99)is now available on PerriconeMD.com , Ulta.com, Nordstrom.com, ECScottGroup.com, Bloomingdales.com, NeimanMarcus.com, and Macys.com.

Perricone MD's Acne Relief Collection Expands Its Product Offering

Retrieved on: 
Tuesday, January 4, 2022
Gentle, Acne, Skin, Ulta Beauty, Bacteria, Willowherb, The New York Times, Inflammation, Woman, Organic acid, SAN, Solution, QVC, Macy's, Neiman Marcus, Cosmetics, Sulfur, Dietary supplement, Neuropeptide, Nordstrom

SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- Known for its advancements in skincare formulations, Perricone MD expands its Acne Relief franchise with products that give a boost to the existing acne-fighting regimen.

Key Points: 
  • SAN FRANCISCO, Jan. 4, 2022 /PRNewswire/ -- Known for its advancements in skincare formulations, Perricone MD expands its Acne Relief franchise with products that give a boost to the existing acne-fighting regimen.
  • Unlike other acne solutions on the market, Perricone MD's line selectivelytargets and treats all three culprits of acne excessoil, acne-causing bacteria, and inflammation.
  • The Acne Relief Gentle Exfoliating Tonerlifts impurities and removes all traces of oil, dirt, and debris for a smoother, more even-looking complexion.
  • "Given the success of our Acne Relief Prebiotic Acne Therapy launch in 2019, Perricone MD is excited to expand its current offering with two line extensions that enhance the existing regimen," says Robert Koerner, Perricone MD's Chief Marketing Officer.